MSNews updates are on hold until further notice. Sign-up on our mailing list here to be notified when we are back.
SPMSS Drug Gets FDA Fast-Track
Submitted by art on Fri, 2008-09-05 07:36.
Fast-track designation could help development and speed the review process of dirucotide, for the treatment of secondary progressive MS, now being evaluated in a U.S. Phase 3 trial.
BioMS says about 510 patients have been recruited for the company's U.S. trial at 68 sites and will receive either dirucotide (MBP8298) or a placebo intravenously every six months for two years.